Risk 25 firms of the future: BlackRock

‘Jury out’ on OTC derivatives

Richard Prager and Supurna VedBrat
Richard Prager and Supurna VedBrat, BlackRock

Over-the-counter derivatives have been a popular way for many buy-side firms to take or hedge risk for more than two decades, but they may be about to lose their appeal. Regulatory reform will impose new capital and liquidity constraints on banks, which will filter through to end-users in the form of higher prices. In addition, the regulatory push to central clearing means contracts will become more standardised and attract a host of new fees. It might mean OTC derivatives are no longer the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Register

Want to know what’s included in our free membership? Click here

This address will be used to create your account

Switching CCP – How and why?

As uncertainty surrounding Brexit continues and the impacts of Covid-19-driven market volatility are analysed, it is essential for banks and their end-users to understand their clearing options, and how they can achieve greater capital and cross…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here